INTRODUCTION
The normal level of carbon dioxide (CO 2 ) tension in the arterial blood (PaCO 2 ) results from the relationship between the rate of CO 2 production and the portion of CO 2 eliminated by the lung with alveolar ventilation. Acute hypercapnic respiratory failure (AHRF) is more commonly determined by a defect of this latter mechanism (respiratory pump failure), when the respiratory muscles do not provide sufficient alveolar ventilation to maintain a normal arterial PaCO 2 .
1 A rapid elevation of PaCO 2 leads to a drop in arterial blood pH as a consequence of the lowering of HCO 3 _ /PaCO 2 ratio.
AHRF is classically considered a main feature of advanced chronic obstructive pulmonary disease (COPD), and the role of non-invasive ventilation (NIV) for its treatment is established. 2 However, an imbalance between the increased elastic and resistive load and the reduced capacity of the respiratory pump is not a unique feature of acute exacerbation of COPD (AECOPD). Many other diseases may lead to AHRF, and therefore NIV has been also used in a wide range of other conditions associated with acidosis and hypercapnia, despite most of the studies having been conducted in patients with COPD (see Table 1 ). 3 This review aims to discuss what is known from the present literature and to summarize the main indications of NIV in AHRF in a practical way.
ACUTE EXACERBATION OF COPD
NIV is considered the standard of care in the management of AHRF secondary to AECOPD 4 both in patients with and without previous chronic hypercapnia.
Since the late 1980s, NIV has been used in intensive care units (ICU) and emergency departments. In the first randomized controlled trial, Brochard et al. 5 showed NIV significantly reduced the need for endotracheal intubation (ETI) when compared to standard medical treatment among patients admitted to an ICU with AECOPD. The frequency of complications was significantly lower in the NIV group and the mean hospital stay significantly shorter. The in-hospital mortality rate was also significantly reduced with NIV. A subsequent study confirmed NIV was associated with reduced rates of ETI and mortality. 6 Conti et al. 7 compared NIV and invasive mechanical ventilation (IMV) in 49 patients with an AECOPD who failed standard medical treatment. In these very sick patients, NIV was proven to be non-inferior than ETI and IMV. Moreover, in those patients who could be managed successfully with NIV, there was an advantage both in terms of reduction in ICU stay, readmissions to hospital in the following year and need for de novo long-term oxygen therapy.
The application of NIV in general wards has been also widely investigated in a number of studies. In the largest one, it was confirmed that delivery of NIV in general ward is feasible. 8 In this multicentre UK trial comparing NIV with standard therapy, early institution of NIV reduced treatment failure and halved hospital mortality. From a post hoc subgroup analysis, data emerged suggesting a worse outcome in patients with pH 7.30. Thus, sicker, more acidotic patients should be monitored more closely in order to avoid delays in intubation.
In a prospective pilot cohort study conducted by Fiorino et al. in a non-'highly protected' environment in a medical ward of a rural hospital, 9 NIV produced similar improvements in arterial blood gases not only in patients with mild, but also with severe forms of respiratory acidosis. The favourable results of this prospective study, and of another retrospective one 10 may be related to the long-term experience of the staff with NIV and the improved technology of ventilators and interfaces, compared with Plant et al.'s study. 8 The benefits of NIV and its non-inferiority to standard therapy have been confirmed in a large number of other randomized controlled trial (RCT) in many different settings, in different countries and healthcare systems.
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Several large surveys showed that the use of NIV has become widespread in the treatment of AECOPD in Europe and in the United States. [12] [13] [14] Nowadays, NIV can be delivered safely in any dedicated setting, ranging from emergency departments, medical units to high-dependency and ICU. Of note, however, NIV should be performed by adequately trained staff with the availability of appropriate monitoring facilities because despite increasing experience with this technique, the rate of NIV failure remains high at 20% and 30% in patients with COPD admitted to ICU, especially in those patients with severe dyspnoea. 15, 16 A successful outcome is highly dependent on accurate patient selection and among patients with COPD the severity of hypercapnia and/or acidosis after initiation of NIV is a major predictor of NIV failure. [17] [18] [19] As remarked in recent ATS/ERS guidelines, 4 strong evidence supports the use of NIV in patients who develop AHRF (pH ≤ 7.35, PaCO 2 > 45 mm Hg) due to AECOPD.
Within this group, we can identify less severely ill patients with a pH of 7.25-7.35. For these patients, NIV could be useful to prevent the progression of acidosis and the requirement of ETI and mechanical ventilation (MV). For the more severely ill patients, typically with a pH < 7.25, instead of being a preventive tool, NIV can represent an alternative to ETI. There is no lower limit of pH below which a trial of NIV is inappropriate; however, the lower the pH, the greater the risk of failure, and patients must be very closely monitored with rapid access to ETI and IMV if not improving. Therefore, a cautious trial of NIV can be considered, unless the patient is immediately deteriorating. When compared to IMV, successful NIV reduces the duration of ICU and hospital stay, the number of hospital readmissions in the subsequent year, 7 ventilator-associated pneumonia and the requirement for tracheostomy. 20 Coma has been classically described as a contraindication to NIV, but the clinically favourable response of a subset patients with hypercapnic encephalopathy has made this statement questionable. [21] [22] [23] Conversely, NIV is not recommended for patients with AECOPD and hypercapnia who do not have acidosis. 4, [24] [25] [26] [27] [28] Hence, in these patients with hypercapnia but no acidosis, the pillars of treatment are medical therapy and, most importantly, correct titration of oxygen, targeted to a saturation of 88-92%, 29 as hyperoxygenation is a cause of acidosis and hypercapnia. 30 In recent years, significant emphasis has been placed on the possible use of new techniques, such as highflow nasal cannula (HFNC). HFNC delivers a mix of air and oxygen with an inspired oxygen fraction (FiO 2 ) ranging between 0.21 and 1.0, and with a range of possible gas flows (1-60 L/min).The gas undergoes 100% humidification and is heated to approximately normal body temperature. Over the last 10 years, HFNC have had widespread uptake in the adult population, due to its versatility and ease of use. The main fields of application of HFNC are still the treatment of acute hypoxaemic respiratory failure, that is not a specific topic of this review, [31] [32] [33] or prevention of post-extubation respiratory failure. 34 The HFNC seems more effective than conventional oxygen therapy and non-inferior to NIV in most studies conducted among hypoxaemic patients. Another issue is that of hypercapnic patients. However, HFNC has also been recently proposed in hypercapnic acute and chronic respiratory failure. HFNC can provide several benefits in these populations, such as maintenance of a constant and accurate FiO 2 , generation of a positive end-expiratory pressure (PEEP), reduction of the anatomical dead space, improvement of mucociliary clearance and reduction in the work of breathing. 35, 36 It is presumed that these benefits may help in reducing or at least in getting under control alveolar hypoventilation, making HFNC a valid support to use with NIV or as an alternative to it for the less severe patients (i.e. for patients who are hypercapnic, but not acidotic). However, this matter will have to be further discussed and confirmed in future RCT. During an episode of AHRF, Lee et al. in a prospective observational trial compared the effectiveness of HFNC and NIV and did not find any difference in intubation rate and 30-day mortality between the two groups. 37 Certainly, most of the studies showed that HFNC is consistently better tolerated by patients than NIV, as mask intolerance is one of the main causes of NIV failure, leading to ETI. Optimization of the treatment includes Weaning from invasive mechanical ventilation 5
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Miscellaneous (very old patients, community-acquired pneumonia and bridge to transplantation) the appropriate selection of the interfaces (material, fit, size and type) in order to minimize complications such as decubitus injuries and claustrophobia. Anxiety and delirium are important issues in critical care environment, and their occurrence is high both in ICU 38 and in respiratory intensive care. 39 Delirium is associated with increased mortality especially in patients undergoing NIV, as demonstrated by Chan et al., who reported an augmented risk for the occurrence of early death of 4.4 in this group of patients. 40 Judicious use of sedation during NIV could be a valuable option. However, although widely used in clinical practice, sedation during NIV has been investigated only in a few studies. [41] [42] [43] [44] [45] [46] [47] The current limited data available suggest that it could be safe and feasible. Remifentanil or dexmedetomidine could have the most suitable overall profile, while benzodiazepines should generally be avoided, as well as haloperidol or atypical antipsychotics. 48, 49 However, more widespread application and the determination of the 'ideal' sedative or analgesic drug to be used during NIV, as well as the best route and modalities of administration, should await the results of further RCT.
CARDIOGENIC PULMONARY OEDEMA
Cardiogenic pulmonary oedema (CPE) frequently leads to acute respiratory failure (ARF), sometimes associated with hypercapnia, mostly in patients with a preexisting chronic lung disease (CLD). 50 Around 20-50% of patients with severe CPE have hypercapnia and this is considered as a marker of severity associated with a higher risk of intubation. 51 In general, in this subset of patients, the rate of NIV success is very high (96%). 52 Continuous positive airway pressure (CPAP) and NIV represent the first line of treatment together with standard medical therapy in acute CPE.
Nevertheless, CPAP can not be considered a 'real' form of MV, as it does not provide support during the inspiratory phase, but a constant positive pressure is applied to raise functional residual capacity and open flooded alveoli. NIV or so-called bilevel ventilation (i.e. the combination of inspiratory pressure and expiratory pressure) is, on the other hand, a 'real' form of ventilation, and therefore theoretically more appropriate when the respiratory pump is failing.
In the subset of patients with hypercapnia, a multicentre study comparing NIV with standard oxygen, the former decreased the need for intubation, and was associated with a reduction in hospital mortality, and similar rates of myocardial infarction. 53 When a head-to-head comparison between CPAP and NIV was performed, NIV accelerated the improvement of ARF compared to CPAP but did not affect primary clinical outcomes (i.e. death and intubation) either in overall population or in subgroups of patients with hypercapnia or those with high B-type natriuretic peptide. 54 Similar results were obtained by Bellone et al. demonstrating NIV was as effective as CPAP in the treatment of patients with CPE and hypercapnia, but did not improve resolution time. 55 In 2008, Grey et al. published the largest multicentre trial, in which >1000 patients were randomized to CPAP, NIV or standard oxygen therapy. This trial found physiological improvement in the CPAP and bilevel NIV groups compared with the standard group, but no difference in intubation rate or mortality at 7 and 30 days. Although a pH of <7.35 was one of the inclusion criteria, only <20% of the patients were affected by a chronic respiratory disorder. 56 Five systematic reviews subsequent to this investigation concluded CPAP and NIV are equivalent and superior to standard oxygen in reducing intubation rate and mortality, but still did not clarify which one of the two techniques should be preferentially used in patients with hypercapnia. [57] [58] [59] [60] [61] Hence, either NIV or CPAP is recommended for patients with ARF due to CPE, even in the pre-hospital setting. 4, 62 In case of hypercapnia, NIV could theoretically be the preferred choice for its greater action on alveolar hypoventilation.
Moreover, clinicians should be aware that patients with CPE presenting with severe hypercapnia (PaCO 2 > 60 mm Hg) may require particular attention. Contou et al. demonstrated that among patients treated for severe CPE and having no identified underlying CLD, severe hypercapnia at admission correlates with a longer duration of NIV without an increase in intubation rate. 63 
OBESITY AND OHS
Respiratory involvement in obese patients is complex and includes pulmonary abnormalities, impairment of central respiratory control and sleep-related breathing disorders. 64 Although obesity is frequent in patients with COPD, asthma and sleep apnoea-hypopnea syndrome (SAHS), a minority of obese subjects develop obesity hypoventilation syndrome (OHS), defined by a body mass index (BMI) >30 kg/m 2 and chronic alveolar hypoventilation leading to daytime hypercapnia. 64 There is a paucity of data regarding the use of NIV in obese patients, most of which arises from case series, often retrospective, with limited patient numbers. [65] [66] [67] Rabec et al. showed that patients with AHRF and OHS can be successfully treated with NIV, as most of them improved PaCO 2 and avoided ETI. 68 Similar results were obtained by Duarte et al., who demonstrated that in 50 morbidly obese patients with AHRF, NIV avoided ETI in the majority of cases. 69 In addition, hospital mortality for the IMV and NIV failure group was higher compared with those successfully managed with NIV.
Bry et al. showed that among 77 obese adults admitted in an ICU because of ARF, subjects with the most severe obesity or who experienced the most difficult initial ventilation were at higher risk of receiving longterm NIV. 70 However, NIV at home was effective and well tolerated.
Not all the patients with OHS, undergoing AHRF, require long-term NIV, as a significant proportion can be managed with CPAP while others can be weaned completely. 71 Carillo et al. compared outcomes in patients with AHRF due to OHS or COPD, who were treated with NIV. 72 Patients with OHS had less late NIV failure, lower hospital mortality and higher 1-year survival. Among patients with COPD, obesity was associated with less late NIV failure and hospital readmission. Interestingly, both COPD and OHS patients were ventilated using the same settings, while in clinical practice the two groups commonly receive different levels of inspiratory and expiratory pressures.
Despite the large clinical use of NIV in AHRF due to OHS, we are still lacking RCT, and therefore no recommendation has been given by the ERS/ATS guidelines. 4 
WEANING FROM IMV
Prolonged intubation and MV are related to high morbidity and mortality, 73, 74 and a strategy to accelerate the process of weaning is expected to improve patient prognosis and to shorten the ICU length of stay.
In the majority of cases, withdrawal of MV is possible immediately after resolution of the underlying problems responsible for ARF. However, there is a group of ventilated patients, namely those with a preexisting respiratory disease and persisting hypercapnia, who require more gradual and longer withdrawal of MV.
In patients with ventilator-dependent hypercapnia and COPD, NIV has been shown to be as effective as IMV in reducing inspiratory effort and improving arterial blood gases. 75, 76 Patients who failed a T-piece trial were randomized to either extubation, with immediate application of NIV, or continued weaning with the endotracheal tube in place. Overall, this study showed that when NIV is used as a weaning technique, the likelihood of weaning success is increased, while the duration of MV and ICU stay decreased.
A second RCT was conducted on patients with CLD, intubated during an episode of ARF. 77 This study pointed out a shorter duration of IMV in the groups weaned non-invasively, although no differences were found in ICU or hospital stay or 3-month survival.
Further studies were performed over the following years. Burns et al. 78 identified 16 RCT enrolling 994 participants overall, mostly with COPD. Compared with conventional weaning, NIV was associated with a significant decrease in mortality, ventilator-associated pneumonia, ICU and hospital length of stay and total duration of MV, especially in the subset of patients with a preexisting CLD.
Considering these findings, recent guidelines 4 suggest the application of NIV to facilitate weaning from MV in patients with AHRF.
PREVENTION OF POST-EXTUBATION FAILURE IN THOSE PATIENTS PREVIOUSLY INTUBATED
Post-extubation failure is a major clinical problem in ICU. 79 Two randomized trials have been performed to assess whether NIV is effective in preventing the occurrence of post-extubation failure in patients at risk, most of them affected by hypercapnia after the removal of endotracheal tube. 80, 81 Both studies showed that the groups treated with NIV had a lower rate of reintubation; furthermore, a post hoc analysis of the latter trial showed that ICU mortality was also reduced in the subgroup of patients with hypercapnia treated with NIV. A subsequent RCT performed in this specific condition has confirmed this important result. 82 Two smaller single-centre trials also randomized patients to receive NIV or standard treatment after planned extubation. 83, 84 Khilnani et al. enrolled patients with COPD only and found no differences regarding intubation rate and ICU and hospital lengths of stay. Ornico et al. enrolled mostly patients with AECOPD and found a significant reduction in the rates of reintubation and deaths in the NIV group.
In conclusion, promptly initiated NIV for at least 48 h in selected 'at-risk' patients may prevent postextubation respiratory failure, especially in those patients with persistent hypercapnia.
CHEST WALL DISEASES AND NEUROMUSCULAR DISEASES
In patients with neuromuscular diseases (NMD) and chest wall diseases (CWD), the decrease in respiratory muscle strength (resulting in ineffective alveolar ventilation), altered rib cage compliance and weakness of expiratory muscles (leading to inadequate clearance of airway secretions) are causes of chronic hypercapnic respiratory failure (HRF), that during exacerbations, may lead to potentially life-threatening problems. 85 The NMD can be classified into two main categories, according to the clinical onset of AHRF: (i) slowly progressive NMD with acute exacerbation of chronic respiratory failure and (ii) rapidly progressive NMD. Motor neurone diseases, spinal muscular atrophy (SMA) and inherited myopathies (i.e. Duchenne muscular dystrophy) are the most frequent slowly progressive NMD, while myasthenia gravis (MG), Guillain-Barré syndrome (GBS) and inflammatory myopathies are the most common rapidly progressive, and potentially reversible, NMD. 86 Treatment of chronic ventilatory failure with nocturnal NIV combined with mechanically assisted coughing is the standard of care in adults and children with HRF secondary to slowly progressive disorders and CWD. 87 Very little is known about the use of NIV during an episode of AHRF, despite the fact that NMD account for about 10% of ICU admissions. 88 Among patients with neuromuscular respiratory failure, those without a known diagnosis before ICU admission have poorer outcomes. 89 A recent Cochrane review 90 found no RCT using NIV to treat an acute exacerbation in NMD and RTD patients.
Flandreau et al. 91 described the outcome of 87 NMD patients experiencing their first AHRF episode requiring ICU admission. Among patients with hereditary diseases and acquired diseases, respectively, the rates of NIV use during the ICU stay were 82% and 63% and the intubation rates were 30% and 56%. At hospital discharge, 46% of the patients were on NIV and 29% had tracheotomy.
Vianello et al. 92 showed that NIV combined with mini-tracheotomy decreased the mortality and ICU stay versus IMV in 14 patients with hypercapnic ARF due to slowly progressive NMD.
An observational study found that NIV was effective in avoiding tracheal intubation in 79% of the 17 NMD patients enrolled. 93 Only three small studies have been published on the use of NIV in patients with MG, [94] [95] [96] and only two case reports in patients with GBS. 97, 98 NIV was shown to prevent intubation in patients with myasthenic crisis, but this effect was observed only in patients without hypercapnia.
While 'chronic' NIV is the standard of care in CWD and NMD patients, we are still lacking RCT during AHRF.
PALLIATIVE CARE AND DNI PATIENTS
NIV may be used as a ceiling treatment, merely as a palliative tool to relieve dyspnoea, in critically ill patients with end-stage disease. A European survey carried out in several respiratory ICU found that up to 22% of those admitted to hospital in a terminal phase of their disease, received this treatment. 99 Palliative care usually concerns cancer patients, but also refers to subjects with end-stage chronic respiratory failure. Chronic hypercapnia and dyspnoea are typical features of the advanced phase of these respiratory diseases and breathlessness also occurs in these terminal patients as a consequence of AECOPD or cardiac failure. 100 Patients and their families expect symptomatic relief of devastating symptoms, such as dyspnoea, pain, anxiety and fear of death.
Despite the best possible medical management, almost all the patients with end-stage cancer or respiratory diseases experience breathlessness, and NIV can help relieve their suffering and eventually to die peacefully. [101] [102] [103] A multicentre RCT showed a significantly greater reduction in breathlessness, especially in the hypercapnic subgroup of patients, when NIV was compared to standard oxygen therapy. 102 Interestingly, the authors also showed that NIV might reduce the dose of morphine necessary to palliate dyspnoea, maintaining better cognitive function. Overall, NIV had a similar rate of acceptance by patients compared with oxygen therapy (60%). 102 Hence, NIV has become part of the therapeutic armamentarium of palliative care. 103, 104 However, although it is considered a 'noninvasive' technique, the use of NIV in a palliative care setting may be controversial. First, this is because the patient may not tolerate NIV well, with undesirable side effects such as skin lesions, irritation of the eyes and claustrophobia. Second, it is thought that NIV may unduly delay death. 105, 106 Therefore, the decision to stop or continue NIV in this scenario is not based on an 'objective' physiological variable, but only on the patient's wishes.
A particular issue for using NIV as a palliative tool is that of patients bearing a do-not-intubate (DNI) order (patients with life-threatening ARF who refuse intubation/tracheostomy). 6, 107, 108 In this respect, NIV may be used palliatively but also with a 'curative' aim. The latter would be the case in a reversible cause of ARF, despite these patients frequently experiencing severe respiratory acidosis and hypercapnia with associated encephalopathy, which are potential predictors of NIV failure. We lack RCT in this scenario, but in observational studies, the use of NIV in patients with 'DNI' was associated, at least in some subsets of patients (COPD and congestive heart failure), with a surprisingly high (>30-60%) hospital survival and a 3-month quality of life equivalent to patients treated with NIV and having no limitation placed on support. 109 The use of NIV is becoming increasingly popular in patients with DNI or as a palliative tool in terminally ill patients, but clinicians should have very clear goals regarding therapy in these patients.
MISCELLANEOUS (VERY OLD PATIENTS, CAP AND BRIDGE TO TRANSPLANTATION)
The proportion of elderly people among hospitalized patients, including ICU admissions, is rapidly growing in developed countries. According to recent epidemiological studies, very old patients (i.e. those older than 80 years) represent 10-15% of ICU admissions. 110, 111 A large observational study on 1019 patients needing ventilatory support showed that 376 (37%) received NIV. Among them, 163 (16%) very old patients (>80 years) received ventilatory support, with 60% of them managed with NIV compared with 32% of younger patients. Hospital mortality was higher in very old than in younger patients but interestingly it did not differ when NIV was used for AHRF due to CPE or acuteon-chronic respiratory failure. The 6-month mortality was 51% in very old patients, 67% for patients with 'DNI' and 77% in case of NIV failure and ETI. 112 There are a few other smaller observational studies, showing that NIV may be useful to treat AHRF in old or very old patients, with an average mortality rate of <40%. [113] [114] [115] The only RCT in these patients was performed by Nava et al. enrolling 82 patients older than 75 years. 116 During an episode of AHRF in old patients with a preexisting CLD, the use of NIV was associated with a lower proportion of patients meeting ETI criteria, a higher survival rate and faster resolution of respiratory distress when compared with standard treatment. The use of NIV as a rescue therapy was associated with a lower mortality rate compared with ETI.
Concerning de novo ARF, recent guidelines 4 were unable to offer a recommendation on the use of NIV in this area. Despite this, some RCT in patients with community-acquired pneumonia (CAP) have demonstrated that NIV is associated with a reduced need for ETI. [117] [118] [119] [120] [121] However, in real life, potential harms of NIV exist. For example, patients with pneumonia who received NIV were 56% more likely to require intubation than patients with COPD who received NIV, and no survival benefits were observed in Medicare patients comparing NIV and IMV. [122] [123] [124] [125] The treatment of respiratory failure due to pneumonia with NIV may also lead to greater mortality than other modes of non-invasive oxygen supplementation such as HFNC. 31 Interestingly, only one study has considered the use of NIV in CAP and AHRF in patients with a preexisting CLD. 119 Fifty-five patients were randomized to NIV or standard treatment. Subgroup analysis showed that patients randomized to NIV had a reduced need for intubation and a better 2-month survival. However, this was not confirmed among those patients with 'pure hypoxia', suggesting that in AHRF associated with CAP, NIV may be of some benefit.
Many patients with cystic fibrosis (CF) develop respiratory failure from progressive airway obstruction and bronchiectasis and when the disease becomes more severe, hypercapnia may ensue. 126 At this stage, NIV may focus on alleviating both the symptomatic and physiological effects of respiratory failure. 1, 127 Patients with CF or bronchiectasis may suffer AHRF during an exacerbation of moderate to severe disease, or indeed without any identified specific acute cause. In this population, NIV ameliorates dyspnoea and avoids ETI and its complications. [128] [129] [130] [131] Moreover NIV could sustain life until more definitive life prolonging treatment could be offered; NIV as a 'bridge' to transplant has become routine at centres capable of performing lung transplant for CF. 129, [131] [132] [133] However, to date, only modest evidence supports the use of NIV in patients with CF, and there were no long-term data on its safety or efficacy.
CONCLUSIONS
When respiratory pump failure occurs, leading to AHRF, NIV is a therapeutic option of paramount importance.
Large data sets from RCT conducted in populations of hypercapnic patients demonstrate that the principal indications are AECOPD and CPE; however, benefits have also been shown when NIV is applied to OHS and obese patients, who develop hypercapnia. NIV is indicated during weaning from MV and for prevention of post-extubation failure in patients at risk of developing HRF. A further field of application of this technique is NMD and CWD, not only in the chronic, but also in the acute setting. Another point of note is the use of NIV in palliative care and in patients with a DNI order. In these patients, NIV has proved to be a valuable tool for relieving symptoms and sometimes for correcting AHRF. In CF, future RCT evaluating a larger population for a longer period of time are need to assess the efficacy and the role of NIV as a treatment of AHRF or as a 'bridge' to transplant. Abbreviations: AECOPD, acute exacerbation of COPD; AHRF, acute HRF; ARF, acute respiratory failure; CAP, communityacquired pneumonia; CF, cystic fibrosis; CLD, chronic lung disease; CO 2 , carbon dioxide; CPAP, continuous positive airways pressure; CPE, cardiogenic pulmonary oedema; CWD, chest wall diseases; DNI, do not intubate; ETI, endotracheal intubation; FiO 2 , inspired oxygen fraction; GBS, Guillain-Barré syndrome; HFNC, high-flow nasal cannula; HRF, hypercapnic respiratory failure; ICU, intensive care unit; IMV, invasive MV; MG, myasthenia gravis; MV, mechanical ventilation; NIV, noninvasive ventilation; NMD, neuromuscular disease; OHS, obesity hypoventilation syndrome; PaCO 2 , CO 2 tension in the arterial blood; RCT, randomized controlled trial.
